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ABSTRACT 
The transcription factor Keap1-Nrf2 system plays a key role in inflammation 
which is involved in depression. We found lower expression of Keap1 and Nrf2 
proteins in the prefrontal cortex (PFC), CA3 and dentate gyrus (DG) of hippocampus in 
mice with depression-like phenotype compared to control mice. Serum levels of 
pro-inflammatory cytokines in Nrf2 knock-out (KO) mice were higher than those of 
wild-type mice, suggestive of enhanced inflammation in KO mice. Decreased 
brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-receptor-kinase 
B (TrkB) signaling in the PFC, CA3 and DG plays a role in the depression-like 
phenotype of Nrf2 KO mice. TrkB agonist 7,8-dihydroxyflavone, but not antagonist 
ANA-12, produced antidepressant effects in Nrf2 KO mice, by stimulating TrkB in the 
PFC, CA3 and DG. Pretreatment with Nrf2 activator sulforaphane (SFN) prevented the 
depression-like phenotype induced after repeated social defeat stress. Interestingly, 
dietary intake of 0.1% glucoraphanin (a precursor of SFN) containing food during 
juvenile and adolescent stages also prevented the depression-like phenotype evoked in 
adulthood, after repeated social defeat stress. These findings suggest that Keap1-Nrf2 
system plays a key role in depression and that dietary intake of SFN-rich food during 
juvenile stages and adolescence can confer stress resilience in adulthood. 
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INTRODUCTION 
Depression is one of the most common psychiatric disorders in the world. The 
World Health Organization estimates that more than 350 million individuals of all ages 
suffer from depression, highlighting this illness as a major contributor to the global 
burden of disease
1,2
. For this reason, new therapeutic approaches are needed to prevent 
or delay the progression of depression. Over the past decade, there has been increasing 
interest in the potential benefits of early intervention for psychiatric disorders. 
Accumulating evidence suggests that nutrition has a high impact on the development of 
depression
3-7
. Recent meta-analyses demonstrated that high intake of fruit, vegetables, 
fish, and whole grains are associated with a reduced risk of depression
8,9
. 
Neurodevelopment in early adolescence is a key stage during maturation, characterized 
by various structural, neurochemical, and molecular changes in response to genetic and 
environmental cues. The formation of new neuronal connections during this 
developmental window also confers a high level of vulnerability to pathologic insults, 
ranging from stress to dietary deficiencies
10,11
. Taken together, nutritional status during 
early adolescence has a great impact on the onset and severity of psychiatric diseases in 
adulthood
11
.  
Although the precise mechanisms underlying the pathophysiology of depression 
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are unknown, several lines of evidence implicate inflammatory processes in the 
development of depression
12-17
. Previous reports including meta-analysis demonstrated 
higher levels of pro-inflammatory cytokines in the blood of drug-free depressed patients 
compared to healthy controls
18-20
. Some studies using postmortem brain samples 
showed elevated gene expression of pro-inflammatory cytokines in patients with a 
history of depression
21,22
. Taken together, it is likely that both peripheral and central 
inflammation plays a crucial role in the pathophysiology of depression. 
Nuclear factor (erythroid 2-derived)-like 2 (Nrf2) is a transcription factor with a 
central role in cellular defense against oxidative and electrophilic insults
23-26
. It binds to 
antioxidant response elements (ARE) located in the promoter region of genes encoding 
many phase II detoxifying or antioxidant enzymes and related stress-responsive 
proteins
23-26
. Under normal conditions, Nrf2 is repressed by Keap1 (Kelch-like 
erythroid cell-derived protein with CNC homology [ECH]-associated protein 1), which 
is an adaptor protein for the degradation of Nrf2
25,26
. During oxidative stress, Nrf2 is 
de-repressed and activates the transcription of cytoprotective genes
25,26
. Additionally, 
the Keap1-Nrf2 system is also involved in attenuating inflammation-associated 
pathogenesis
24-28
. 
The potent anti-inflammatory and naturally occurring compound sulforaphane 
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(SFN: 1-isothiocyanato-4-methylsulfinylbutane) is an organosulfur compound derived 
from a glucosinolate precursor  glucoraphanin (GF: a glucosinolate, or 
β-thioglucoside-N-hydroxysulfate) found in cruciferous vegetables, such as broccoli 
sprout
29-34
. It is well known that GF can be converted to SFN by the endogenous 
enzyme, myrosinase
34
. The protection afforded by SFN is thought to be mediated via 
activation of the Nrf2 pathway with subsequent up-regulation of phase II detoxification 
enzymes and antioxidant proteins, through an enhancer sequence referred to as the 
electrophilic-responsive element or ARE
25,26
. 
The purpose of this study was to examine the role of Keap1-Nrf2 signaling in the 
pathophysiology of depression using the potent Nrf2 activator, SFN and Nrf2 knock-out 
(KO) mice. In addition, we examined the role of brain-derived neurotrophic factor 
(BDNF) and its receptor tropomyosin-receptor-kinase B (TrkB) signaling in selected 
brain regions, since BDNF-TrkB signaling is integral to the pathophysiology of 
depression
35-42
. Finally, we examined whether dietary intake of 0.1% GF food during 
the juvenile and adolescence can prevent depression-like behaviors by repeated social 
defeat stress. 
MATERIALS AND METHODS 
Cell culture and quantification of neurite outgrowth 
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PC12 cells (RIKEN Cell Bank, Tsukuba, Japan) were cultured at 37℃, 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 5% heat-inactivated 
fetal bovine serum (FBS), 10% heat-inactivated horse serum and 1% penicillin. Medium 
was changed two to three times a week. PC12 cells were plated onto 24-well tissue 
culture plates coated with poly-D-lysine/laminin. Cells were plated at relatively low 
density (0.25 × 104 cells/cm2) in DMEM medium containing 0.5% FBS, 1% 
penicillin-streptomycin. Medium containing a minimal level of serum (0.5% FBS) was 
used as previously reported
71
. Twenty-four hours after plating, the medium was replaced 
with DMEM medium containing 0.5% FBS and 1% penicillin-streptomycin with nerve 
growth factor (NGF: 2.5 ng/ml), with or without SFN (0.01, 0.1 or 1.0 µM). 
Four days after incubation with NGF (2.5 ng/ml) with or without specified drugs, 
morphometric analysis was performed on digitized images of live cells taken under 
phase contrast illumination, with an inverted microscope linked to a camera. Images of 
three fields per well were taken, with an average of 100 cells per field. Differentiated 
cells were counted by visual examination of the field; only cells that had at least one 
neurite with a length equal to the cell body diameter were counted, and were then 
expressed as a percentage of the total cells in the field. Counting was performed in a 
blinded manner. Data were expressed as a percentage of control group (NGF alone). 
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Cells were fixed for 30 min at room temperature (RT), with 4% paraformaldehyde, 
permeabilized with 0.2% Triton and then blocked with 5% normal horse serum, in 0.1 
M phosphate-buffer saline for 1 h, to reduce nonspecific binding. Cells were incubated 
overnight at 4 ℃  with anti-microtubule-associated protein 2 (MAP-2) antibodies 
(1:1000 dilution in blocking solution, Chemicon International, Temecula, CA, USA). 
Immunolabeling was visualized with secondary antibodies conjugated to Alexa-488 
(1:1000; Invitrogen, Carlsbad, CA, USA). MAP-2 immunocytochemistry was 
visualized by fluorescence microscopy (Axiovert 200, Carl Zeiss, Oberkochen, 
Germany). 
Animals 
Male adult C57BL/6 mice, aged 8 weeks (body weight 20-25g, Japan SLC, Inc., 
Hamamatsu, Japan), CD1 mice, aged 14 weeks (body weight 40-45g, Japan SLC, Inc., 
Hamamatsu, Japan) and male adult Nrf2 homozygous KO mice (Nrf2
-/-
) mice
72
 were 
used in experiments. Male C57BL/6 mice, aged 5 weeks (Japan SLC, Inc., Hamamatsu, 
Japan) were used in the experiment of dietary intake of 0.1% glucoraphanin (GF) food 
pellet. Animals were housed under controlled temperature and 12 hour light/dark cycles 
(lights on between 07:00-19:00), with ad libitum food and water. All experiments were 
carried out in accordance with the Guide for Animal Experimentation of Chiba 
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University. The protocol was approved by the Chiba University Institutional Animal 
Care and Use Committee. 
Prepare of 0.1% glucoraphanin (GF) diet  
Food pellets (CE-2; Japan CLEA, Ltd., Tokyo, Japan) containing 0.1% glucoraphanin 
(GF) were prepared as follows. Broccoli sprout extract powder containing SFN 
precursor GF was industrially produced by KAGOME CO., LTD. In brief, broccoli 
sprout was grown from specially selected seeds (Brassica Protection Products LLC., 
Baltimore, MD, USA) for 1 day after the germination. The 1 day broccoli sprout was 
plunged into boiling water and maintained at 95°C for 30 minutes, and the sprout 
residues was removed by filtration. The boiling water extract was mixed with a waxy 
corn starch dextrin and then spray dried to yield the broccoli sprout extract powder 
containing 135 mg (approx. 0.31 mmol) of GF per gram. For preparing the animal diet 
containing 0.1% GF (approx. 2.3 mmol GF per 1 kg-diet), the extract powder was 
mixed with a basal diet CE-2, and then pelletized at a processing facility (Oriental Yeast 
Co., ltd., Tokyo, Japan). The GF content in the diet was determined by high 
performance liquid chromatography as previously described
73,74
. 
Drugs and treatment 
On the day of injection, fresh solutions were prepared by dissolving compounds in 
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sterile endotoxin-free isotonic saline. (R,S)-sulforaphane (SFN; 10 mg/kg, LKT 
Laboratories, Inc., St Paul, MN, USA) was dissolved in distilled water including 10% 
corn oil. 7,8-Dihydroxyflavone (7,8-DHF: 10 mg/kg, Catalog number: D1916, Tokyo 
Chemical Industry, Tokyo, Japan) was prepared in a vehicle of 17% dimethylsulfoxide 
(DMSO) in phosphate-buffered saline (PBS). ANA-12, N2-(2-{[(2-oxoazepan-3-yl) 
amino]carbonyl}phenyl)benzo[b] thiophene-2-carboxamide (0.5 mg/kg, Catalog 
number: BTB06525SC, Maybridge, UK), was dissolved in 1% DMSO in physiological 
saline. SFN, 7,8-DHF or ANA-12 were administered intraperitoneally (i.p.) into mice. 
The dose of SFN (10 mg/kg), 7,8-DHF(10 mg/kg) and ANA-12 (0.5 mg/kg) was 
selected as previously reported
44-50
. 
Social defeat procedure 
The procedure for inducing social defeat stress was performed as previously reported
48, 
59, 75
. Briefly, C57BL/6 mice were exposed to a different CD1 aggressor mouse each day 
for 10 min for 10 days. After the social defeat session, the resident CD1 mouse and the 
intruder mouse were housed in one half of the cage separated by a perforated Plexiglas 
divider to allow visual, olfactory, and auditory contact for the remainder of the 24-h 
period. At 24 h after the last session, all mice were housed individually. On day 11, a 
social avoidance test was performed to identify subgroups of mice that were susceptible 
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and unsusceptible to social defeat stress. Approximately 70 % of mice were susceptible 
in this study. Only susceptible (depressive-like behavior) mice were used in the 
subsequent experiments. 
A social interaction test was performed on one day after the last social defeat 
session. For this test, an open field arena (42×42 cm) was divided into an interaction 
zone and two opposing corner zones. A mesh-plastic target box (10×4.5 cm) was placed 
into the interaction zone. A test mouse was allowed to roam around the open field arena 
for 2.5 min with no social target (CD1 mouse) in the mesh box (denoted as ‘no target’ in 
figures showing results of social-interaction experiments). After this, a novel CD1 
mouse was placed in a metal mesh-plastic target box in the interaction zone (denoted as 
‘target’ in figures showing results of social-interaction experiments) and the test mouse 
was placed back into the open arena for another 2.5 min. Using the stopwatch, the 
amount of time spent in the interaction zone (defined as the 8-cm-wide area surrounding 
the wiremesh cage) was measured each with or without social target in 2.5 min
76
. 
Behavioral tests 
Behavioral tests were performed as reported previously46-48,59. Locomotion: the mice 
were placed in experimental cages (length × width × height: 560 × 560 × 330 mm). 
Locomotor activity of mice was counted by the SCANETMV-40 (MELQUEST Co., 
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Ltd., Toyama, Japan), and cumulative exercise was recorded for 60 minutes. Cages were 
cleaned between testing session. Tail suspension test (TST): The mice were taken from 
their home cage and a small piece of adhesive tape was placed approximately 2 cm from 
the tip of their tail. A single hole was punched in the tape and mice were hung 
individually, on a hook. The immobility time of each mouse was recorded for 10 
minutes. Mice were considered immobile only when they hung passively and 
completely motionless. Forced swimming test (FST): The mice were placed 
individually in a cylinder (diameter: 23 cm; height: 31 cm) containing 15 cm of water, 
maintained at 23 ± 1℃. Animals were tested in an automated forced-swim apparatus 
using SCANETMV-40 (MELQUEST Co., Ltd., Toyama, Japan). Immobility time was 
calculated from activity time as (total) – (active) time, using the apparatus analysis 
software. Cumulative immobility time was scored for 6 minutes during the test. Sucrose 
preference test (SPT): Mice were habituated to a 1% sucrose solution for 48 h before the 
test day. Mice were deprived of water and food for 4 h, followed by a preference test 
spanning 1 h with water and 1% sucrose, delivered from identical bottles. The bottles 
containing water and sucrose were weighed before and at the end of this period and the 
sucrose preference was determined. 
Western blot analysis 
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The brain samples of CA1, CA3 and DG of the hippocampus, prefrontal cortex (PFC) 
and NAc from mice were dissected as previously reported
47,48,59
. Tissue samples or 
PC12 cells were homogenized in Laemmli lysis buffer. Aliquots (10 μg for mice brain 
sample and 30 μg for cell sample) of protein were measured using the DC protein assay 
kit (Bio-Rad, Hercules, CA, USA), and incubated for 5 min at 95 °C, with an equal 
volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol, 0.1% bromophenol blue, 10% 
β-mercaptoethanol, 4% sodium dodecyl sulfate, and subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, using 10% mini-gels (Mini-PROTEAN TGX 
Precast Gel; Bio-Rad). Proteins were transferred onto polyvinylidenedifluoride (PVDF) 
membranes using a Trans Blot Mini Cell (Bio-Rad). For immunodetection, the blots 
were blocked with 2% BSA in TBST (TBS + 0.1% Tween-20) for 1 h at room 
temperature (RT), and kept with primary antibodies overnight at 4°C. The following 
primary antibody was used: nuclear factor (erythroid 2-derived)-like 2 (Nrf2) (1: 1000, 
Abcam), Kelch-like erythroid cell-derived protein with CNC homology 
[ECH]-associated protein 1(Keap1) (1: 1000, Abcam) brain derived neurotrophic factor 
(BDNF) (1: 1000, Santa Cruz Biotechnology, Inc., CA), phosphor-TrkB (Tyr 706) 
(1:200, Santa Cruz Biotechnology, Inc., CA), postsynaptic density protein 95 (PSD-95) 
(1 µg/ml Invitrogen, Carlsbad, CA), and glutamate receptor 1 (GluA1) (1 µg/ml Abcam, 
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Cambridge, MA). The next day, blot were washed three times in TBST and incubated 
with horseradish peroxidase conjugated anti-rabbit antibody (1:5000 for Nrf2, BDNF, 
PSD-95 and GluA-1; 1:1000 for TrkB) and goat anti-rabbit antibody (1:5000 for keap1, 
1:2000 for p-TrkB) 1 hour, at RT. After final three washes with TBST, bands were 
detected using enhanced chemiluminescence (ECL) plus the Western Blotting Detection 
system (GE Healthcare Bioscience). The blots then were incubated in the stripping 
buffer (2% SDS, 100 mM β-mercaptoethanol, 62.5 mM Tris-HCl PH 6.8) for 30 min at 
60°C followed by three time washed with TBST. The stripped blots were kept blocking 
solution for 1 hour and incubated with the primary antibody directed against TrkB 
(80E3) (1:1000, Cell Signaling Technology, MA) and β-actin. Images were captured 
with a Fuji LAS3000-mini imaging system (Fujifilm, Tokyo, Japan), and 
immunoreactive bands were quantified. 
Measurement of pro-inflammatory cytokines 
The WT mice and KO mice were anesthetized with pentobarbital, and blood was 
collected from heart. Blood was centrifuged at 2,000 g for 20 minutes to generate serum 
samples. The serum samples were diluted 10-fold with ELISA diluent solution 
(eBioscience, San Diego, CA, USA). The serum levels of tumor necrosis factor (TNF)-α, 
interlukin-6 (IL-6), interlukin-10 (IL-10) and interlukin-1β (IL-1β) concentrations were 
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measured using a Ready-SET-Go ELISA kit (eBioscience, San Diego, CA, USA) 
according to the manufacturer’s instructions.  
Statistical Analysis 
The data are shown as the mean ± standard error of the mean (S.E.M.). Analysis was 
performed using PASW Statistics 20 (formerly SPSS statistics; SPSS, Tokyo, Japan). 
Comparisons between groups were performed using the Student’s t-test, one-way 
analysis of variance (ANOVA), followed by post-hoc Tukey test or two-way ANOVA, 
when appropriate, post-hoc comparisons were performed using the unpaired t-test. The 
P values of less than 0.05 were considered statistically significant. 
RESULTS 
Role of Nrf2 in SFN-induced potentiation of NGF-induced neurite outgrowth. 
Since the current antidepressants are known to affect the neuronal plasticity, we 
examined the effects of SFN on nerve growth factor (NGF)-induced neurite outgrowth 
in PC12 cells. MAP-2 (microtubule associated protein-2) immunocytochemistry showed 
that SFN increased the number of cell with neurite outgrowth in PC12 cells (Fig. 1a). 
SFN (0.01, 0.1 or 1.0 µM) significantly (one-way ANOVA: F3,38 = 7.010, P = 0.001) 
increased the number of cells with neurite outgrowth in PC12 cells, in a 
concentration-dependent manner (Fig. 1b). 
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To investigate whether Nrf2 plays a role in SFN’s potentiation of NGF-induced 
neurite outgrowth, we examined the effect of Nrf2 gene knock-down. One-way ANOVA 
of neurite outgrowth data revealed significant effects (F5,47 = 38.56, P < 0.001), the 
potentiating effects of SFN (1.0 µM) on NGF-induced neurite outgrowth were 
significantly attenuated by treatment with Nrf2 siRNA, but not the negative control (Fig. 
1c). In contrast, treatment with Nrf2 siRNA or the negative control alone did not alter 
NGF-induced neurite outgrowth in PC12 cells (Fig. 1c). Furthermore, SFN (1.0 µM) 
significantly increased Nrf2 protein in PC12 cells (Fig. 1d). One-way ANOVA revealed 
significant effects (F5,23 = 10.47, P < 0.001). The Nrf2 siRNA, but not negative control 
of siRNA, significantly blocked SFN-induced Nrf2 protein expression. In the absence of 
SFN, Nrf2 siRNA or negative control did not alter basal levels of Nrf2 protein (Fig. 1d). 
These findings suggest that SFN can potentiate NGF-induced neurite outgrowth via 
activation of Nrf2. 
Reduction of Keap1-Nrf2 signaling in the brain from social defeat stress model of 
depression. 
We performed Western blot analysis of Keap1 and Nrf2 proteins in the brain regions 
(CA1, CA3, dentate gyrus (DG) of hippocampus, prefrontal cortex (PFC), nucleus  
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Figure 1. Potentiation of neurite outgrowth by SFN. (a): Representative photographs of 
microtubule-associated protein 2 (MAP-2) immunocytochemistry in PC12 cells. Control: NGF (2.5 
ng ml-1) alone, SFN: NGF (2.5 ng ml-1) + SFN (1.0 µM). (b): Effects of SFN on NGF-induced 
neurite outgrowth in PC12 cells. SFN (0.01, 0.1 or 1.0 µM) potentiated NGF-induced neurite 
outgrowth in PC12 cells, in a concentration-dependent manner. All data represent the mean ± S.E.M. 
(n = 6-12) *P < 0.05, ***P < 0.001 as compared with the control group (one-way ANOVA). (c): The 
potentiating effects of SFN (1.0 µM) on NGF-induced neurite outgrowth were significantly 
antagonized by treatment with Nrf2 siRNA, but not negative siRNA. Neither Nrf2 siRNA nor 
negative siRNA alone altered NGF (2.5 ng ml
-1
)-induced neurite outgrowth. All data represent the 
mean ± S.E.M. (n = 8). ***P < 0.001 as compared with the SFN (1.0 µM) group (one-way ANOVA). 
(d): The potentiating effects of SFN (1.0 µM) on Nrf2 protein levels were significantly antagonized 
by treatment with Nrf2 siRNA, but not the negative siRNA. In contrast, neither Nrf2 siRNA nor 
negative siRNA alone altered levels of Nrf2 protein in the control (NGF (2.5 ng ml
-1
)-treated) group. 
All data represent the mean ± S.E.M. (n = 4). *P < 0.05, **P < 0.01 as compared with the SFN (1.0 
µM) group (one-way ANOVA).  
accumbens (NAc)) of susceptible mice by social defeat stress model. Protein levels of 
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Keap1 and Nrf2 in the CA3, DG, and PFC from mice with depression-like phenotype 
were significantly lower than those of control mice (Fig. 2a and 2b). In contrast, protein 
levels of Keap1 and Nrf2 in the CA1 and NAc were not different (Fig. 2a and 2b). 
These findings suggest that decreased levels of Keap1 and Nrf2 in the CA3, DG, and 
PFC may be implicated in the pathophysiology of depression after social defeat stress. 
 
Figure 2. Protein levels of Nrf2 and Keap1 in the brain from mice with depression-like 
phenotype. (a and b): The levels of Nrf2 and Keap1 proteins in the mouse brain regions from social 
defeat stress (susceptible) mice and control mice (n = 5 or 6). Data represent the mean ± S.E.M. *P < 
0.05 and **P < 0.01 compared with the control group (Student t-test).  
Depression-like phenotypes, altered BDNF-TrkB signaling and inflammation in 
Nrf2 KO mice. 
Locomotion showed no difference (P = 0.702) between the two groups (Fig. 3a). In the 
tail-suspension test (TST) and forced swimming test (FST), the immobility times of 
Nrf2 KO mice were significantly (TST: P = 0.034; FST: P = 0.017) higher than those of 
wild-type (WT) mice (Fig. 3a). In the 1% sucrose preference test (SPT), the sucrose 
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preference of Nrf2 KO mice was significantly (P = 0.009) lower than that of WT mice 
(Fig. 3a). In addition, the total fluid intake (FIT) for SPT in WT mice and Nrf2 KO mice 
was not different (Fig. 3a). These findings show that Nrf2 KO mice have 
depression-like phenotype including anhedonia. 
Since BDNF-TrkB signaling plays a key role in depression-like phenotype in 
rodents
35-42
, we examined the role of BDNF-TrkB signaling in the selected brain regions 
of Nrf2 KO mice. Western blot analyses of BDNF, TrkB, and phosphorylated TrkB 
(p-TrkB) in the selected brain regions (CA1, CA3, DG, PFC, NAc) from WT mice and 
Nrf2 KO mice were performed. Protein levels of BDNF in the CA3, DG and PFC of 
Nrf2 KO mice were significantly (CA3: P = 0.024, DG: P = 0.029, PFC: P = 0.041) 
lower than those of WT mice. Furthermore, the ratio of p-TrkB to total TrkB in the CA3, 
DG, and PFC of KO mice was also significantly (CA3: P = 0.004, DG: P = 0.036, PFC: 
P = 0.031) lower than that of WT mice (Fig. 3b). In contrast, the levels of BDNF and the 
ratio of p-TrkB to total TrkB in the CA1 and NAc remained the same (Fig. 3b). 
Next, we measured the markers (AMPA receptor 1 (GluA1), and postsynaptic 
density protein 95 (PSD-95)) for synaptogenesis. Protein levels of GluA1 and PSD-95 
in the CA3, DG, and PFC of KO mice were significantly (CA3: GluA1, P < 0.001, 
PSD-95, P < 0.001, DG: GluA1, P = 0.041, PSD-95, P = 0.001, PFC: GluA1, P < 0.001; 
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PSD-95: P < 0.001) lower than those of WT mice, although levels of GluA1 and 
PSD-95 in the CA1 and NAc were unaltered (Fig. 3c). 
Furthermore, we measured the serum levels of pro-inflammatory cytokines, 
including tumor necrosis factor (TNF)-α, interlukin-6 (IL-6), interlukin-10 (IL-10) and 
interlukin-1β (IL-1β) in WT mice and Nrf2 KO mice. Serum levels of TNF-α (P = 
0.046), IL-6 (P = 0.038), IL-10 (P = 0.005) and IL-1β (P = 0.040) in the Nrf2 KO mice 
were significantly higher than those of WT mice, suggesting that Nrf2 KO mice have 
inflammation (Fig. 3d). 
Antidepressant effect of TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) in Nrf2 KO 
mice. 
Since Nrf2 KO mice showed decreased BDNF-TrkB signaling in the CA3, DG and PFC, 
we examined whether the TrkB agonist 7,8-DHF
43-48
 shows antidepressant effects in 
depression-like phenotype of Nrf2 KO mice. A single dose of 7,8-DHF (10 mg/kg) had 
no effect on locomotion (Fig.4a). In the TST and FST, 7,8-DHF (10mg/kg) significantly 
attenuated the increased immobility time of Nrf2 KO mice. In the TST, two-way 
ANOVA revealed significant effects (genotype: F1,39 = 7.134, P = 0.011, treatment: F1,39 
= 4.912, P = 0.033, interaction: F1,39 = 7.679, P = 0.009) (Fig. 4a). In the FST, two-way 
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Figure 3. Depression-like phenotypes of Nrf2 KO mice and inflammation in Nrf2 KO mice. (a): 
The behavior tests in WT and Nrf2 KO mice. Locomotion (LMT); tail-suspension test (TST); forced 
swimming test (FST), 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. 
Data represent the mean ± S.E.M (n = 9 or 10). *P < 0.05, **P < 0.01 compared with the WT group 
(Student t-test). (b and c): Western blot of BDNF, p-TrkB/TrkB, PSD-95 and GluA-1 in WT and 
Nrf2 KO mice. Data represent the mean ± S.E.M (n = 5 or 6). *P < 0.05, **P < 0.01, ***P < 0.001 
compared with the WT group (Student t-test). (d): Serum levels of TNF-α, IL-6, IL-10 and IL-1β in 
WT and Nrf2 KO mice. Data represent the mean ± S.E.M (n = 9-12). *P < 0.05, **P < 0.01 
compared with the WT group (Student t-test). 
ANOVA revealed significant effects (genotype: F1,39 = 5.756, P = 0.022, treatment: F1,39 
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= 5.434, P = 0.026, interaction: F1,39 = 0.495, P = 0.486) (Fig. 4a). Furthermore, 
7,8-DHF (10 mg/kg) significantly attenuated the decreased sucrose preference of Nrf2 
KO mice. Two-way ANOVA revealed significant effects (genotype: F1,40 = 5.194, P = 
0.029, treatment: F1,40 = 10.25, P = 0.003, interaction: F1,40 = 11.41, P = 0.002) (Fig. 4a). 
In addition, the total FIT for SPT among four groups was not different (Fig. 4a). These 
findings suggest that a TrkB agonist 7,8-DHF showed antidepressant effects in the Nrf2 
KO mice. 
A single administration of 7,8-DHF (10mg/kg) significantly attenuated the 
decreased ratio of p-TrkB to total TrkB in the CA3, DG and PFC of Nrf2 KO mice. 
Two-way ANOVA revealed significant effects (CA3, genotype: F1,21 = 5.512, P = 0.031, 
treatment: F1,21 = 14.02, P = 0.001, interaction: F1,21 = 13.44, P = 0.002; DG, genotype: 
F1,21 = 5.461, P = 0.031, treatment: F1,21 = 6.425, P = 0.021, interaction: F1,21 = 6.200, P 
= 0.023, PFC: genotype: F1,21 = 4.948, P = 0.039, treatment: F1,21 = 16.53, P = 0.001, 
interaction: F1,21 = 14.43, P = 0.001) (Fig. 4b). However, there were no changes in the 
CA1 and NAc (Fig. 4b). 
In contrast, a single administration of TrkB antagonist ANA-12 (0.5 mg/kg)
45-48,49
 
did not affect depression-like phenotype in Nrf2 KO mice (Fig. 4c), suggesting a role of 
TrkB signaling in the PFC and hippocampus for depression-like phenotype. In addition, 
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a single administration of SFN (10mg/kg)
50-52
 did not affect depression-like phenotype 
in Nrf2 KO mice (Fig. 4d), suggesting a role of Nrf2 in depression-like phenotype. 
 
Figure 4. Antidepressant effect of 7,8-DHF, a TrkB agonist, in Nrf2 KO mice. (a) 7,8-DHF (10 
mg/kg) or vehicle (10 ml/kg) was administered i.p. into WT and Nrf2 KO mice. Behavioral tests 
were performed 1 hour after injection. Locomotion (LMT); tail-suspension test (TST); forced 
swimming test (FST), 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. 
Data represent the mean ± S.E.M. (n = 9-11). *P< 0.05, **P < 0.01, ***P < 0.001 compared with 
vehicle-treated KO group (two-way ANOVA). (b): Levels of p-TrkB/TrkB ratio in the mouse brain 
regions after injection of 7,8-DHF. Data represent the mean ± S.E.M (n = 5 or 6). **P < 0.01, ***P < 
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0.001 compared with vehicle-treated KO group (two-way ANOVA). (c) ANA-12 did not show 
antidepressant effect in the Nrf2 KO mice. ANA-12 (0.5 mg/kg) or vehicle (10 ml/kg) was 
administered i.p. into WT and Nrf2 KO mice. Behavioral tests were performed 1 hour after injection. 
Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST); 1% sucrose preference 
test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 8 -11). 
*P< 0.05, **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA). (d) 
SFN did not show antidepressant effect in the Nrf2 KO mice. SFN (10 mg/kg) or vehicle (10 ml/kg) 
was administered i.p. into WT and Nrf2 KO mice. Behavioral tests were performed 1 hour after 
injection. Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST), 1% sucrose 
preference test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 
10-11). **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA). 
Pretreatment with SFN prevented the onset of depression-like behavior by 
repeated social defeat stress. 
The aforementioned findings suggest that Nrf2 plays a key role in pathophysiology of 
depression. In this study, we examined whether pretreatment with SFN could prevent 
depression-like phenotype by repeated social defeat stress (Fig. 5a). In the social 
interaction test (no target), the social interaction time has no significant changes in all 
groups (Fig. 5b).  In the social interaction test (target), SFN significantly attenuated the 
decreased social avoidance time in stressed mice (Fig. 5c). Two-way ANOVA on the 
data (target) revealed significant effects (stress: F1,47 = 88.28, P < 0.001, SFN: F1,47 = 
13.56, P = 0.001, interaction: F1,47 = 13.89, P = 0.001) (Fig. 5c). In the SPT, SFN 
significantly attenuated the decreased sucrose preference of stressed mice (Fig. 5d). 
Two-way ANOVA revealed significant effects (stress: F1,50 = 24.20, P < 0.001, SFN: 
F1,50 = 9.238, P = 0.004, interaction: F1,50 = 2.478, P = 0.122) (Fig. 5d). In addition, the 
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total FIT for SPT among four groups was not different (Fig. 5e). 
Next, we performed Western blot analyses of Keap1, Nrf2, BDNF, TrkB, and 
p-TrkB in the selected regions. We found that pretreatment with SFN significantly 
attenuated the decreased levels of Keap1 and Nrf2 in the CA3, DG, and PFC of stress 
mice (Fig. 5f and g). Two-way ANOVA of Keap1 and Nrf2 data revealed significant 
effects (Keap1: CA3, stress: F1,21 = 5.332, P = 0.033, treatment: F1,21 = 5.161, P = 0.036, 
interaction: F1,21 = 2.335, P = 0.144; DG, stress: F1,21 = 7.190, P = 0.015, treatment: F1,21 
= 5.617, P = 0.029, interaction: F1,21 = 6.914, P = 0.017; PFC, stress: F1,21 = 9.795, P = 
0.006, treatment: F1,21 = 16.948, P = 0.001, interaction: F1,21 = 12.540, P = 0.002; Nrf2: 
CA3, stress: F1,21 = 4.804, P = 0.042, treatment: F1,21 = 5.653, P = 0.029, interaction: 
F1,21 = 0.739, P = 0.401; DG, stress: F1,21 = 19.848, P < 0.001, treatment: F1,21 = 17.549, 
P = 0.001, interaction: F1,21 = 16.206, P = 0.001; PFC, stress: F1,21 = 14.039, P = 0.001, 
treatment: F1,21 = 10.845, P = 0.004, interaction: F1,21 = 3.363, P = 0.083)( Fig. 5f and 
g). 
Pretreatment with SFN significantly attenuated the decreased levels of BDNF in 
the CA3, DG, and PFC from stressed mice. In contrast, pretreatment with SFN 
significantly attenuated the increased levels of BDNF in the NAc from stressed mice 
(Fig. 5h). Two-way ANOVA of BDNF data revealed significant effects (CA3, stress: 
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F1,21 = 4.653, P = 0.045, treatment: F1,21 = 12.28, P = 0.003, interaction: F1,21 = 34.12, P 
< 0.001; DG, stress: F1,21 = 14.37, P = 0.001, treatment: F1,21 = 4.998, P = 0.038, 
interaction: F1,21 = 3.277, P = 0.087; PFC, stress: F1,21 = 18.86, P < 0.001, treatment: 
F1,21 = 10.06, P = 0.005, interaction: F1,21 = 4.587, P = 0.046; NAc, stress: F1,21 = 5.388, 
P = 0.032, treatment: F1,21 = 6.961, P = 0.017, interaction: F1,21 = 1.958, P = 0.179)(Fig. 
5h). 
To clarify whether TrkB activation or inhibition underpins depression-like 
phenotype in stressed (susceptible) mice, we performed the immunoblot blot analyses of 
TrkB and phosphorylated TrkB (p-TrkB), an activated form of TrkB in the brain regions. 
Stressed mice showed decreased levels of p-TrkB in the CA3, DG, and PFC as well as 
increased levels of p-TrkB in the NAc. In contrast, the levels of total TrkB protein were 
not altered among the four groups. Pretreatment with SFN significantly attenuated the 
decreased ratio of p-TrkB to total TrkB in CA3, DG and PFC of stressed mice (Fig. 5i). 
In contrast, pretreatment with SFN significantly attenuated the increased levels of 
p-TrkB to total TrkB in NAc from stressed mice (Fig. 5i). Two-way ANOVA of 
p-TrkB/TrkB ratio revealed significant effects (CA3, stress: F1,20 = 6.296, P = 0.023, 
treatment: F1,20 = 13.243, P = 0.002, interaction: F1,20 = 4.205, P = 0.056; DG, stress: 
F1,20 = 5.868, P = 0.027, treatment: F1,20 = 4.638, P = 0.046, interaction: F1,20 = 29.69, P 
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< 0.001; PFC, stress: F1,21 = 7.379, P = 0.014, treatment: F1,21 = 11.79, P = 0.003, 
interaction: F1,21 = 11.53, P = 0.003; NAc, stress: F1,21 = 25.65, P < 0.001, treatment: 
F1,21 = 17.77, P = 0.001, interaction: F1,21 = 2.017, P = 0.173) (Fig. 5i). 
 
Figure 5. Pretreatment with SFN prevents depression after repeated social defeat stress. (a): 
The schedule of treatment and behavioral evaluations. (b): Social interaction test (SIT): no target, 
(c): SIT: target. (d): 1% sucrose preference test (SPT), (e) total fluid intake test (FIT) for SPT. Data 
represent the mean ± S.E.M. (n = 10-14). *P < 0.05, ***P < 0.001 compared with the vehicle-treated 
stress group (two-way ANOVA). (f and g): Western blot of Nrf2, Keap1 in the mouse brain regions. 
Data represent the mean ± S.E.M. (n = 5 or 6). *P < 0.01, **P < 0.01, ***P < 0.001 compared with 
the vehicle-treated stressed group (two-way ANOVA). (h and i): Western blot of BDNF, 
p-TrkB/TrkB in the mouse brain regions. Data represent the mean ± S.E.M. (n = 5 or 6). *P < 0.01, 
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**P < 0.01, ***P < 0.001 compared with the vehicle-treated stress group (two-way ANOVA).  
Dietary intake of 0.1% glucoraphanin during the juvenile and adolescence can 
prevent depression-like behaviors by repeated social defeat stress 
Nutritional status during juvenile and adolescence has a great impact on the onset and 
severity of psychiatric diseases in adulthood
10,11
.
 
Mice (5-weeks old) were received 
dietary intake of 0.1% GF containing food pellets for 21 days. Subsequently, repeated 
social defeat stress was performed for 10 days (Fig. 6a). Pellet including 0.1% GF was 
prepared as reported previously
52
. In the social interaction test (no target), the social 
interaction time for all groups was not different (Fig. 6b). In the social interaction test 
(target), mice with pellets including 0.1% GF significantly attenuated the decreased 
social avoidance time in stress mice (Fig. 6c). Two-way ANOVA revealed significant 
effects (stress: F1,64 = 54.90, P < 0.001, treatment: F1,64 = 5.011, P = 0.029, interaction: 
F1,64 = 3.927, P = 0.052) (Fig. 6c). In the SPT, treatment with pellets including 0.1% GF 
significantly attenuated the decreased sucrose preference of stressed mice. Two-way 
ANOVA analysis of SPT data revealed significant effects (stress: F1,64 = 5.844, P = 
0.019, treatment: F1,64 = 4.382, P = 0.040, interaction: F1,64 = 2.971, P = 0.090) (Fig. 6d). 
In addition, the total FIT for SPT among the four groups was not different (Fig. 6e). 
These findings suggest that dietary intake of 0.1% GF can prevent the onset of 
depression-like phenotype by repeated social defeat stress. 
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Figure 6. Dietary intake of 0.1% GP during the juvenile and adolescence prevents depression 
after repeated social defeat stress. 
(a): The schedule of dietary intake of 0.1% glucoraphanin (GP) and behavioral evaluations. (b): 
Social interaction test (SIT): no target, (c): SIT: target, (d): 1% sucrose preference test (SPT), (e): 
total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 16 or 17). *P < 0.05, **P 
< 0.01, ***P < 0.001 compared with the vehicle-treated stressed group (two-way ANOVA). 
DISCUSSION 
The present data demonstrated a key role for the Keap1-Nrf2 system in the 
pathophysiology of depression. The major findings of this study were: First, through 
Nrf2 activation, SFN can potentiate NGF-induced neurite outgrowth in PC12 cells, 
indicating that Nrf2 activators such as SFN are capable of enhancing the neuronal 
plasticity. Secondly, Nrf2 and Keap1 proteins showed decreased expression in the CA3, 
DG, and PFC of mice with depressed-like phenotype after repeated social defeat stress. 
Thirdly, Nrf2 KO mice displayed a depression-like phenotype including anhedonia, 
while the TrkB agonist 7,8-DHF promoted an antidepressant effect in Nrf2 KO mice. 
However, neither the TrkB antagonist ANA-12 nor the Nrf2 activator SFN had an effect 
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on the depression-like phenotype seen in Nrf2 KO mice. It is likely that decreased 
BDNF-TrkB signaling and synaptogenesis in the CA3, DG, and PFC of Nrf2 KO mice 
promotes the depression-like phenotype of these KO mice. Moreover, serum levels of 
pro-inflammatory cytokines in Nrf2 KO mice were higher than those of WT mice, 
suggesting that Nrf2 KO mice show enhanced inflammation. Lastly, pretreatment with 
SFN significantly attenuated the decreased social avoidance time and sucrose preference 
in repeated social defeat stress mice. Interestingly, dietary intake of 0.1% GF pellets 
during juvenile and adolescent stages significantly attenuated the decreased social 
avoidance time and sucrose preference in repeated social defeat stress mice during 
adulthood. All these findings implicate the Keap1-Nrf2 system in the pathophysiology 
of depression, as well as suggesting that the dietary intake of 0.1% GF pellets during 
juvenile and adolescent development may confer stress resilience in adulthood. 
A microarray study showed that loss of Nrf2 gene altered the expression of various 
categories of genes associated with metabolism, channel or transport activity, 
receptor-mediated signal transduction, cell adhesion and transcriptional regulation
53
. 
Interestingly, the expression levels of detoxification enzyme genes, such as 
sulfotransferase 1B1 (Sult1b1), glutathione-S-transferase (GST) M1 (Gstm1), GSTM3 
(Gstm3) and aldehyde oxidase 1 (Aox1), were decreased in the brain regions of Nrf2 
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KO mice
53
. Given the role of oxidative stress in depression
54,55
, it is likely that 
decreased levels of these genes in the brain may be involved in the depression-like 
phenotype of Nrf2 KO mice although a further detailed study is needed. In this study, 
we found that social defeat stress significantly decreased the levels of Nrf2 and Keap1 
protein in the hippocampus and PFC. Moreover, SFN could attenuate the decreased 
levels of Nrf2 and Keap1 proteins in the hippocampus and PFC of stress mice. These 
results suggest that Keap1-Nrf2 signaling may play a role in the pathophysiology of 
depression, and that SFN is prophylactic compound which can stimulate Keap1-Nrf2 
signaling pathway. 
BDNF-TrkB signaling plays a key role in the pathophysiology of depression
35-42
. 
Studies using postmortem brain samples recorded reduced levels of BDNF in the 
hippocampus and PFC of psychiatric disorder patients who had committed suicide, 
compared with non-psychiatric controls
56,57
. Recently, we reported that BDNF levels in 
hippocampus and PFC of mice with depression-like phenotype were lower than control 
mice, conversely, BDNF levels in the NAc of mice with depression-like phenotype were 
higher than control mice
47,48, 58,59
. A single infusion of BDNF or the TrkB agonist, 
7,8-DHF into the DG and CA3 of the hippocampus promoted rapid and long-lasting 
antidepressant effects in learned helplessness models of depression
60,61
, whereas a single 
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infusion of ANA-12 into the NAc showed antidepressant effects
61
. The loss of BDNF in 
the forebrain attenuated the action of antidepressants
62
, and responses elicited by 
antidepressants were lost in mice with either reduced brain BDNF levels or inhibited 
TrkB signaling
63,64
. These results suggest that abnormal BDNF levels in the 
hippocampus and PFC, and the NAc play a causative role in the pathophysiology of 
depression. In this study, we detected decreased BDNF-TrkB signaling in the CA3, DG 
and PFC of Nrf2 KO mice. We also found that the TrkB agonist, 7,8-DHF conferred an 
antidepressant effect, by stimulating TrkB in these regions. Thus, it is likely that 
decreased BDNF-TrkB signaling in CA3, DG and PFC regions, precipitated by a 
deletion of the Nrf2 gene, may mediate depression-like phenotypes in Nrf2 KO mice. 
Previous reports also showed that Nrf2 KO mice show depression-like phenotype
65
, and 
that BDNF levels in the cortex and hippocampus of Nrf2 KO mice were lower than 
control mice
66
. The precise mechanisms underlying decreased BDNF levels in the PFC 
and hippocampus of Nrf2 KO mice are currently unknown. Further detailed studies on 
the role of Nrf2 in BDNF-TrkB signaling in the brain are needed. Previously, we 
reported that TrkB antagonist ANA-12 showed antidepressant effect by inhibiting TrkB 
signaling pathway in the NAc of mice with depression-like phenotye
47,48
. In this study, 
TrkB antagonist ANA-12 did not show antidepressant effect since the BDNF-TrkB 
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signaling was not increased in the NAc of Nrf2 KO mice. 
Growing evidence suggests that inflammatory processes play a role in the 
pathophysiology of depression
12-17
. In this study, we found increased serum levels of 
pro-inflammatory cytokines, such as TNF-α, IL-6, IL-10 and IL-1β, in Nrf2 KO mice, 
indicating increased inflammation in these mice. Thus, it seems that abnormal 
pro-inflammatory cytokine levels in the serum of Nrf2 KO mice may play a causative 
role in the pathophysiology of depression, since higher levels of these cytokines were 
detected in the blood of patients with depression
67,68
. Recently, we reported that a single 
administration of lipopolysaccharide (LPS) induced higher serum levels of these 
cytokines and a depression-like phenotype in mice
47
, suggesting an inflammation model 
of depression. Given the role of Keap1-Nrf2 signaling in inflammation, the 
depression-like phenotype of Nrf2 KO mice is noteworthy, consistent with previous 
report showing that Nrf2 KO mice exhibit an increase of inflammatory markers
65
. 
Although the reasons underlying inflammation in Nrf2 KO mice are currently unknown, 
it seems that microgliosis due to the lack of Nrf2 may lead to activation of NF-κB, AP-1 
and their up-regulating kinases which, in turn, increase the production of 
pro-inflammatory cytokines
65
. 
Nutritional status during early adolescence has a great impact on the onset and 
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severity of psychiatric diseases in adulthood
10,11
. Over the past decade, there has been 
increasing interest in the potential benefits of early intervention for psychiatric 
diseases
10,11
. Therefore, it is of great interest to study whether dietary intake of 0.1% GF 
during juvenile and adolescence phases can prevent the depression-like behavior in 
adulthood, after repeated social defeat stress. Here, we found that dietary intake of 0.1% 
GF during juvenile and adolescence phases was capable of preventing depression-like 
behavior in adulthood, after repeated social defeat stress. A recent randomized, 
double-blinded, placebo-controlled study demonstrated that treatment with SFN-rich 
broccoli sprout extract significantly improved social interaction, abnormal behavior and 
verbal communication in young men with autism spectrum disorder
69
. In addition, we 
reported that supplementation with GF-rich broccoli sprout extract for eight weeks was 
effective in treating cognitive impairment in medicated patients with schizophrenia
70
. 
Although the precise mechanisms underlying the prophylactic and therapeutic effects of 
SFN are currently unknown, dietary intake of SFN-rich broccoli sprout extract may be 
able to regulate gene expression through epigenetic mechanisms. 
There is a limitation of this study. In this study, we used the schedule of dietary 
intake of 0.1% GF during juvenile and adolescent stages (from 5-weeks old to 8-week 
old), indicating that GF (or SFN) in the body may affect behavioral effects. Previously, 
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we reported that dietary intake of 0.1% GF during juvenile and adolescent stages (from 
4-week old to 8-week old) and subsequent normal pellet (from 8-week old to 10-week 
old) could prevent phencyclidine-induced cognitive deficits in adulthood
52
. It is, 
therefore, of great interest to study whether dietary intake of 0.1% GF during juvenile 
and adolescent stages (from 5-week old to 8-week old) and subsequent normal food 
from 8-week old and 10-week old can confer stress resilience in adulthood. 
In conclusion, our study demonstrated that not only is the Keap1-Nrf2 system 
crucial to the pathophysiology of depression, but that decreased BDNF-TrkB signaling 
in the PFC, CA3, and DG plays a role in the depression-like phenotype of Nrf2 KO 
mice. Furthermore, dietary intake of 0.1% GF during mouse juvenile and adolescent 
stages can prevent stress-induced depression-like behavior in adult stages. Therefore, it 
is possible that dietary intake of GF (or SFN) during childhood and adolescence could 
prevent the onset of depression in humans during adulthood. In addition, dietary intake 
of GF (or SFN) may prevent or minimize relapse from remission, induced by 
inflammation and/or stress in depressed patients. 
 
 
 
37 
 
References 
1. Whiteford, H. A., et al. Global burden of disease attributable to mental and 
substance use disorders: findings from the Global Burden of Disease Study 2010. 
Lancet 382, 1575-1586 (2013). 
2. Walker, E. R., McGee, R. E. & Druss, B. G. Mortality in mental disorders and 
global disease burden implications: a systematic review and meta-analysis. JAMA 
Psychiatry 72, 334-341 (2015). 
3. Mukakami, K. & Sasaki, S. Dietary intake and depressive symptoms: a systemic 
review of observational studies. Mol Nutr Food Res 54, 471-488 (2010). 
4. Bazinet, R. P. & Layé, S. Polyunsaturated fatty acids and their metabolites in brain 
function and disease. Nat Rev Neurosci 15, 771-785 (2014). 
5. Mello, A. H., et al. ω-3 and major depression: a review. Acta Neuropsychiatr 26, 
178-185 (2014). 
6. El-Behadli, A. F., et al. Maternal depression, stress and feeding styles: towards a 
framework for theory and research in child obesity. Br J Nutr 113, S55-S71 (2015). 
7. Opie, A., O'Neil, R. S., Itsiopoulos, C. & Jacka, F. N. The impact of whole-of-diet 
interventions on depression and anxiety: a systematic review of randomised 
controlled trials. Public Health Nutr 18, 2074-2093 (2015). 
38 
 
8. Lai, J.S., et al. A systematic review and meta-analysis of dietary patterns and 
depression in community-dwelling adults. Am J Clin Nutr 99, 181-197 (2014). 
9. Liu, X., Yan, Y., Li, F. & Zhang, D. Fruit and vegetable consumption and the risk of 
depression: A meta-analysis. Nutrition 32, 296–302 (2016). 
10. Paus, T., Keshavan, M. & Giedd, J. N. Why do many psychiatric disorders emerge 
during adolescence? Nat Rev Neurosci 9, 947–957 (2008). 
11. O’Connor, R. M & Cryan, J. F. Adolescent brain vulnerability and psychopathology 
through the generations: role of diet and dopamine. Biol Psychiatry 75, 4–6 (2014).  
12. Dantzer, R., et al. From inflammation to sickness and depression: when the immune 
system subjugates the brain. Nature Rev Neurosci 9, 46-57 (2008).  
13. Hashimoto, K. Emerging role of glutamate in the pathophysiology of 
major depressive disorder. Brain Res Rev 61, 105-123 (2009). 
14. Miller, A. H., Maletic, V. & Raison, C. L. Inflammation and its 
discontents: The role of cytokines in the pathophysiology of major 
depression. Biol Psychiatry 65, 732-741 (2009). 
15. Raison, C. L., Lowry, C. A. & Rook, G. A. Inflammation, sanitation, and 
consternation: loss of contact with coevolved, tolerogenic microorganisms and the 
pathophysiology and treatment of major depression. Arch Gen Psychiatry 67, 
39 
 
1211-1224 (2010). 
16. Hashimoto, K. Inflammatory biomarkers as differential predictors of antidepressant 
response. Int J Mol Sci 16, 7796–7801 (2015). 
17. Zhang, J.C., Yao, W. & Hashimoto, K. Brain-derived neurotrophic factor (BDNF) 
– TrkB signaling in inflammation-related depression and potential therapeutic 
targets. Curr Neuropharmacol in press (2016). 
18. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 
67, 446–457 (2010). 
19. Young, J.J., Bruno, D. & Pomara, N. A review of the relationship between 
pro-inflammatory cytokines and major depressive disorder. J Affect Disord 169, 
15–20 (2014).  
20. Haapakoski, R., et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour 
necrosis factor α and C-reactive protein in patients with major depressive disorder. 
Brain Behav Immun 49: 206–215 (2015). 
21. Dean, B., Tawadros, N., Scarr, E. & Gibbons, A. S. Regionally-specific changes in 
levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained 
postmortem from subjects with major depressive disorder. J Affect Disord 120, 245–
248 (2010). 
22. Shelton, R. C. et al. Altered expression of genes involved in inflammation and 
apoptosis in frontal cortex in major depression. Mol Psychiatry 16, 751-762 (2011). 
40 
 
23. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol 
Toxicol 53, 401–426 (2013). 
24. Kobayashi, E., Suzuki, T. & Yamamoto, M. Roles nrf2 plays in myeloid cells and 
related disorders. Oxid Med Cell Longev 2013, 529219 (2013). 
25. Suzuki, T., Motohashi, H. & Yamamoto, M. Toward clinical application of 
the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34, 340–346 (2013). 
26. Suzuki, T. & Yamamoto, M. Molecular basis of the Keap1-Nrf2 system. Free 
Radic Biol Med 88, 93–100 (2015). 
27. O'Connell, M. A. & Hayes, J. D. The Keap1/Nrf2 pathway in health and disease: 
from the bench to the clinic. Biochem Soc Trans 43, 687–689 (2015).  
28. Wardyn, J. D., Ponsford, A. H. & Sanderson, C. M. Dissecting molecular cross-talk 
between Nrf2 and NF-κB response pathways. Biochem Soc Trans 43, 621–626 
(2015). 
29. Zhang, Y., Talalay, P., Cho, C. G. & Posner, G. H. A major inducer of 
anticarcinogenic protective enzymes from broccoli: isolation and elucidation of 
structure. Proc Natl Acad Sci USA 89, 2399–2403 (1992). 
30. Fahey, J. W., Zhang, Y. & Talalay, P. Broccoli sprouts: an exceptionally rich source 
of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad 
41 
 
Sci USA 94, 10367–10372 (1997). 
31. Kensler, T. W. et al. Keap1-Nrf2 signaling: a target for cancer prevention by 
sulforaphane. Top Curr Chem 329, 163–177 (2013). 
32. Juge, N., Mithen, R. F. & Traka, M. Molecular basis for chemoprevention by 
sulforaphane: a comprehensive review. Cell Mol Life Sci 64, 1105–1127 (2007). 
33. Kwak, M. K. & Kensler, T. W. Targeting NRF2 signaling for cancer 
chemoprevention. Toxicol Appl Pharmacol 244, 66–76 (2010). 
34. Fahey, J. W., et al. Sulforaphane bioavailability from glucoraphanin-rich broccoli: 
control by active endogenous myrosinase. PLoS One 10, e0140963 (2015). 
35. Nestler, E. J., et al. Neurobiology of depression. Neuron 34, 13–25 (2002). 
36. Hashimoto, K., Shimizu, E. & Iyo, M. Critical role of brain-derived neurotrophic 
factor in mood disorders. Brain Res Brain Res Rev 45, 104-14 (2004). 
37. Duman, R. S. & Monteggia, L. M. A neutrotrophic model for stress-related mood 
disorders. Biol Psychiatry 59, 1116–1127 (2006). 
38. Hashimoto, K. Brain-derived neurotrophic factor as a biomarker for mood 
disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64, 
341–357 (2010). 
39. Hashimoto, K. Sigma-1 receptor chaperone and brain-derived neurotrophic   
42 
 
factor: emerging links between cardiovascular disease and depression. Prog 
Neurobiol 100, 15–29 (2013). 
40. Castrén, E. Neurotrophins and psychiatric disorders. Handb Exp Pharmacol 220, 
461–479 (2014). 
41. Björkholm, C. & Monteggia, L. M. BDNF- a key transducer of antidepressant 
effects. Neuropharmacology 102, 72–79 (2015). 
42. Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in 
social defeat stress. Science 311, 864–868 (2006). 
43. Jang, S. W. et al. A selective TrkB agonist with potent neurotrophic activities by 
7,8-dihydroxyflavone. Proc Natl Acad Sci USA 107, 2687–2692 (2010). 
44. Ren, Q., et al. Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating 
deficits in mice after administration of methamphetamine. Pharmacol Biochem 
Behav 106, 124–127 (2013). 
45. Ren, Q., et al. 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral 
abnormalities and neurotoxicity in mice after administration of methamphetamine. 
Psychopharmacology (Berl) 231, 159–166 (2014). 
46. Ren, Q., et al. BDNF-TrkB signaling in the nucleus accumbens shell of mice has 
key role in methamphetamine withdrawal symptoms. Transl Psychiatry 5, e666 
43 
 
(2015). 
47. Zhang, J. C. et al. Antidepressant effects of TrkB ligands on depression-like 
behavior and dendritic changes in mice after inflammation. Int J 
Neuropsychopharmacol 18, pii: pyu077 (2015). 
48. Zhang, J. C. et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 
antidepressant effects in the social defeat stress model of depression. 
Psychopharmacology 232, 4325–4335 (2015). 
49. Cazorla, M., et al. Identification of a low-molecular weight TrkB antagonist with 
anxiolytic and antidepressant activity in mice. J Clin Invest 121, 1846–1857 (2011). 
50. Chen, H., et al. Protective effects of the antioxidant sulforaphane on behavioral 
changes and neurotoxicity in mice after the administration of methamphetamine. 
Psychopharmacology (Berl) 222, 37–45 (2012). 
51. Shirai, Y., Fujita, Y. & Hashimoto, K. Effects of the antioxidant sulforaphane on 
hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine 
administration. Clin Psychopharmacol Neurosci 10, 97–98 (2012). 
52. Shirai, Y. et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during 
Juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at 
adulthood. PLoS One 10, e0127244 (2015). 
44 
 
53. Muramatsu, H., et al. Nrf2 deficiency leads to behavioral, neurochemical and 
transcriptional changes in mice. Genes Cells 18, 899–908 (2013). 
54. Black, C. N. et al. Oxidative stress, anti-oxidants and the cross-sectional and 
longitudinal association with depressive symptoms: results from the CARDIA 
study. Transl Psychiatry 6, e743 (2016). 
55. Smaga, I. et al. Oxidative stress as an etiological factor and a potential treatment 
target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and 
autism. Pharmacol Rep 67, 569–580 (2015). 
56. Dwivedi, Y., et al. Altered gene expression of brain-derived neurotrophic factor and 
receptor tyrosin kinase B in postmortem brain of suicide subjects. Arch Gen 
Psychiatry 60, 804–815 (2003). 
57. Karege, F., et al. Neurotrophin levels in postmortem brains of suicide victims and 
the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain 
Res 136, 29–37 (2005). 
58. Yang, C., et al. Regional differences in brain-derived neurotrophic factor levels and 
dendritic spine density confer resilience to inescapable stress. Int J 
Neuropsychopharmacol 18, pyu121 (2015). 
59. Yang, C. et al. R-Ketamine: a rapid-onset and sustained antidepressant without 
45 
 
psychotomimetic side effects. Transl Psychiatry 5, e632 (2015). 
60. Shirayama, Y., et al. Brain-derived neurotrophic factor produces antidepressant 
effects in behavioral models of depression. J Neurosci 22, 3251–3261 (2002). 
61. Shirayama, Y., et al. Alterations in brain-derived neurotrophic factor (BDNF) and 
its precursor proBDNF in the brain regions of a learned helplessness rat model and 
the antidepressant effects of a TrkB agonist and antagonist. Eur 
Neuropsychopharmacol 25, 2449–2458 (2015). 
62. Monteggia, L. M. et al. Essential role of brain-derived neurotrophic factor in adult 
hippocampal function. Proc Natl Acad Sci USA 101, 10827–10832 (2004). 
63. Saarelainen, T. et al. Activation of the TrkB neurotrophin receptor is induced by 
antidepressant drugs and is required for antidepressant-induced behavioral effects. J 
Neurosci 23, 349–357 (2003). 
64. Monteggia, L. M. et al. Brain-derived neurotrophic factor conditional knockouts 
show gender differences in depression-related behaviors. Biol Psychiatry 61, 187–
197 (2007). 
65. Martín-de-Saavedra, M. D. et al. Nrf2 participates in depressive disorders through 
an anti-inflammatory mechanism. Psychoneuroendocrinology 38, 2010–2022 
(2013). 
46 
 
66. Mendez-David, I. et al. Nrf2-signaling and BDNF: A new target for the 
antidepressant-like activity of chronic fluoxetine treatment in a mouse model of 
anxiety/depression. Neurosci Lett 597, 121–126 (2015). 
67. Howren, M. B., Lamkin, D. M & Suls, J. Associations of depression with 
C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med, 71, 171–186 
(2009).  
68. Strawbridge, R., et al. Inflammation and clinical response to treatment in 
depression: A meta-analysis. Eur. Neuropsychopharmacol 25, 1532–1543 (2015). 
69. Singh, K. et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc 
Natl Acad Sci USA 111, 15550–15555 (2014).  
70. Shiina, A. et al. An open study of sulforaphane-rich broccoli sprout extract in 
patients with schizophrenia. Clin Psychopharmacol Neurosci 13, 62–67 (2015). 
71. Ishima, T., et al. Potentiation of neurite outgrowth by brexpiprazole, a novel 
serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A 
receptors. Eur Neuropsychopharmacol 25, 505–511 (2015). 
72. Itoh, K. et al. An Nrf2/small Maf heterodimer mediates the induction of phase II 
detoxifying enzyme genes through antioxidant response elements. Biochem Biophys 
Res Commun 236, 313–322 (1997). 
47 
 
73. Bennett, R. N., et al. Profiling glucosinolates, flavonoids, alkaloids, and other 
secondary metabolites in tissues of Azima tetracantha L. (Salvadoraceae). J Agric 
Food Chem 52, 5856–5862 (2004). 
74. West, L. G., et al. Glucoraphanin and 4-hydroxyglucobrassicin contents in seeds of 
59 cultivars of broccoli, raab, kohlrabi, radish, cauliflower, brussels sprouts, kale, 
and cabbage. J Agric Food Chem 52, 916–926 (2004).  
75. Golden, S. A., Covington, HE. 3rd., Berton, O. & Russo, S. J. A standardized 
protocol for repeated social defeat stress in mice. Nat Protoc 6, 1183–1191 (2011). 
76. Walsh, J. J. et al. Stress and CRF gate neural activation of BDNF in the mesolimbic 
reward pathway. Nat Neurosci 17, 27–29 (2014). 
 
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scientific Reports. 6, 30659 , 2016 公表済 
 
 
 
